Organon EV/EBIT OGN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.

Today, Oct 23, 2026: 9.5×
5-year median: 8.9×
Against its 5-year history: 76th; percentile: 0 is its lowest day, 100 its highest
5-year range: 7.3× to 11.1×
Peer median: 20.0×

Organon's EV/EBIT is 9.5× as of Oct 23, 2026.

That is above its 5-year median of 8.9×, higher than on 76% of days in the last 5 years.

Over that time it ranged from 7.3× in Oct 2022 to 11.1× in Aug 2024.

The median for 10 large drugmakers of a similar size is 20.0×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.5×	7.7×	9.5×
2025	8.0×	7.9×	9.2×
2024	8.8×	8.7×	11.1×
2023	9.8×	8.0×	10.2×
2022	8.3×	7.3×	9.3×

Against its peers

Companies in Drug Manufacturers - General nearest Organon's size, closest first, today.

Company	EV/EBIT
OGNOrganon	9.5×
LQDALiquidia	21.7×
ARQTArcutis Biotherapeutics	111×
INDVIndivior Pharmaceuticals	7.8×
NRIXNurix Therapeutics	7.1×
PBHPrestige Consumer Healthcare	14.5×
KNSAKiniksa Pharmaceuticals International	54.6×
LGNDLigand Pharmaceuticals	57.7×
HRMYHarmony Biosciences	6.9×
AMRXAmneal Pharmaceuticals	18.3×
ALKSAlkermes plc.	69.6×
Peer median	20.0×

Where Organon ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Organon

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.